Progyny, Inc. Common Stock PGNY

Progyny, Inc. es una empresa de gestión de beneficios. La empresa se especializa en soluciones de beneficios de fertilidad y construcción de familias en los Estados Unidos. Los clientes de la empresa incluyen diversos empleadores en una variedad de industrias. Tiene contratos para proporcionar cobertura a aproximadamente 6.4 millones de empleados y sus parejas (conocidos como miembros). La empresa ofrece sus beneficios a través de su enfoque Smart Cycle patentado. Los Smart Cycles incluyen los servicios médicos necesarios para el curso completo de tratamiento de un miembro, incluidas todas las pruebas diagnósticas necesarias y acceso a la tecnología. Además de su solución de beneficios de fertilidad, la empresa ofrece una solución integrada de beneficios farmacéuticos, Progyny Rx, que puede ser agregada por sus clientes. Progyny Rx proporciona a sus miembros acceso a los medicamentos necesarios durante su tratamiento de fertilidad. Ofrece servicios de gestión de cuidados, así como capacitación en administración de medicamentos, servicios de apoyo farmacéutico y apoyo continuo de un defensor del cuidado del paciente.

• Zacks Investment Research 18 sept

  PGNY vs. CRL: Which Stock Is the Better Value Option?

  A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.

  

• Zacks Investment Research 15 sept

  Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?

  Concentra Group (CON) has reached a new 52-week high of $36.05, gaining 82% year-to-date and outperforming its sector. The company maintains a Zacks Rank #1 (Strong Buy) with consistent earnings beat records and a VGM Score of B. However, valuation metrics show the stock trades at a premium to peers (21.7X forward P/E vs. 17X industry average), raising questions about further upside potential.

  

• GlobeNewswire Inc. 7 ago

  Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

  Progyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company recently reported record quarterly revenue, gross profit, and adjusted EBITDA for Q2 2026, with strong demand continuing for its women's health and family building solutions.

  

• The Motley Fool 25 jun

  What Does the Sale of Progyny Shares by the CFO Mean for Investors?

  Progyny CFO Mark Livingston sold 8,275 shares (9.47% of his direct holdings) for $211,000 on May 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The sale is not considered a red flag as it was non-discretionary. Despite losing a major customer, Progyny's shares rose in Q2 after the company provided strong 2026 guidance projecting 6-9% revenue growth, or 10-13% excluding the lost client's prior contributions.